skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: LQDA This company was recommended on BNN. Your opinion of this stock as a possible buy.
Thanks. Cheers
Read Answer Asked by Hans on March 11, 2026
Q: When looking at technical analysis of this company, would one need to ignore the chart action prior to March 2022 because of its spin-off ? - i.e. is it irrelevant to use stock pricing before that date to establish overall long term trend lines and channels for T.A. purposes ?

How do you see this company as an investment going forward, and how do its valuation metrics compare now to the past?
Read Answer Asked by James on March 03, 2026
Q: The sector rotations in the markets are wreaking havoc on my portfolio balance, mostly in a good way. The healthcare sector overall is down and the limited successes seem expensive. Also, the US government is pushing pharma to reduce their margins.
Do you feel that it is a good time to invest in healthcare and if so could you recommend stocks and etfs for broader exposure? For years, the etfs seem to have underperformed.

Thank you!
Read Answer Asked by Peter on March 02, 2026
Q: You seem to really like WELL and feel it is undervalued right now - Is that right ? Please give us an update on WELL as well as AIDX. On February 12 you answered a question regarding AIDX saying there was no news in 2 months. On that same day (likely after you posted your reply) there was in fact news on AIDX as well as more news on Feb 19. Are you liking AIDX more now and if WELL's stock price increases do you think AIDX would follow?
Read Answer Asked by Pierre on February 23, 2026
Q: Good morning, Peter and Team,

Paul Krugman recently wrote the following in a Substack post:

'And the damage from the assault on vaccines continues to widen. Last week the Food and Drug Administration refused to review Moderna’s new mRNA-based flu vaccine. They didn’t reject it based on evidence; they wouldn’t even look at it, in line with RFK Jr.’s evidence-free, dogmatic assertion that mRNA technology, which gave us Covid vaccines, is useless and harmful. Pharmaceutical companies, understandably, are retreating from vaccine development.'

Is this another reason to avoid, or to at least reduce exposure to companies involved in vaccine development? For those of us with ETFs in the Health Care Sector, this becomes a daunting task.

Personally, I can't wait until the US midterms so that hopefully there can be some hope that this madness will end.

As always, thanks for your insights.

Read Answer Asked by Jerry on February 19, 2026
Q: I just sold a position in Regeneron, and I am looking to replace it with another name in the healthcare space. I already hold ISRG, but I am reticent to add to it while it seems to trade sideways. Lilly has performed well, but I am unsure if it is now fully valued.A recent interviewee on CNBC had mentioned Amgen and Gilead as names which could do well. Any suggestions for names to consider in the healthcare space? I’d be okay with both Canadian and US names. Thanks so much, and I look forward to your response.
Read Answer Asked by Domenic on February 18, 2026
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!